UNSPSC 51412402: Efloxate

This classification denotes a vasodilating agent with the molecular formula C19H16O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CZU6V3902K, chemically known as acetic acid, ((4-oxo-2-phenyl-4h-1-benzopyran-7-yl)oxy)-, ethyl ester but generally known as efloxate, which bears US NIH Compound Identifier 8395. European Medicines Agency schedules Efloxate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06469MIG. The term EFLOXATE is an International Non-Proprietary Name.

UNSPSC 51412402 Efloxate, a Commodity code, describes medications and related pharmaceutical products procured by state and local health systems, fire and rescue departments, and health authorities. State and local governments buy emergency pharmaceuticals, generic prescription medications, and over-the-counter products under this code to stock ambulances, fire stations, hospitals, and pharmacy benefit programs. The issuing bodies include city purchasing departments (particularly fire and rescue operations), state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple states and municipalities. Work solicited ranges from single emergency medication line items with fixed expiration and replacement warranties to multistate generic pharmaceutical frameworks serving integrated wholesaler networks across participating jurisdictions.

Recent activity appears centered in Florida and Texas, with multistate cooperative purchasing through Minnesota. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 to supply Advanced Life Support Medications—including Labetalol, Epinephrine, Adenosine, and Diltiazem—for Tampa Fire Rescue, with a firm-price contract valued at $40,000 and a response deadline of April 8, 2026; the contract included a 5 percent Small Local Business Enterprise bid discount. The Texas Health and Human Services Commission posted a Request for Information (RFI No. HHS0017013) on March 27, 2026 to explore vendor capacity for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct contracting strategies outside traditional pharmacy benefit managers and wholesalers. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, with awards to take effect July 1, 2026 through established wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC.